Reevaluating the Role of Direct Antiglobulin Testing in Low-Risk Neonates with ABO or RhD Incompatibility
Routine DAT offers limited additional clinical value over transcutaneous bilirubin monitoring in low-risk ABO and RhD-incompatible neonates, supporting guideline shifts towards selective DAT use and emphasizing maternal antibody screening.
